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Abstract
Predicting antidepressant response has been a clinical challenge for mood disorder. Although 
several genome-wide association studies have suggested a number of genetic variants to be 
associated with antidepressant response, the sample sizes are small and results are difficult to 
replicate. Previous animal studies have shown that knockout of the serotonin receptor 7 gene 
(HTR7) resulted in an antidepressant-like phenotype, suggesting it was important to antidepressant 
action. In this report, in the first stage, we used a cost-effective pooled-sequencing strategy to 
sequence the entire HTR7 gene and its regulatory regions to investigate the association of common 
variants in HTR7 and clinical response to four selective serotonin reuptake inhibitors (SSRIs: 
citalopram, paroxetine, fluoxetine and sertraline) in a retrospective cohort mainly consisting of 
subjects with bipolar disorder (n=359). We found 80 single nucleotide polymorphisms (SNPs) 
with false discovery rate < 0.05 associated with response to paroxetine. Among the significant 
SNPs, rs7905446 (T/G), which is located at the promoter region, also showed nominal 
significance (P < 0.05) in fluoxetine group. GG/TG genotypes for rs7905446 and female gender 
were associated with better response to two SSRIs (paroxetine and fluoxetine). In the second 
stage, we replicated this association in two independent prospective samples of SSRI treated 
patients with major depressive disorder: the MARS (n=253, P=0.0169) and GENDEP studies 
(n=432, P=0.008). The GG/TG genotypes were consistently associated with response in all three 
samples. Functional study of rs7905446 showed greater activity of the G allele in regulating 
expression of HTR7. The G allele displayed higher luciferase activity in two neuronal related cell 
lines, and estrogen treatment decreased the activity of only the G allele. Electrophoretic mobility 
shift assay suggested that the G allele interacted with CCAAT/enhancer-binding protein beta 
transcription factor (TF), while the T allele did not show any interaction with any TF. Our results 
provided novel pharmacogenomic evidence to support the role of HTR7 in association with 
antidepressant response.
Keywords
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Background
Serotonin (5-HT) is a monoamine neurotransmitter with a broad range of physiological 
functions including sleep, mood, cardiovascular function, circadian rhythms, body 
temperature, food intake and endocrine regulation. These effects are mediated by a large 
number of 5-HT receptors, comprising seven families (HTR1 to HTR7) and at least 14 
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subtypes, among which HTR7 displays the highest affinity for 5-HT (1-3). HTR7 is a G-
protein-coupled receptor that links to adenylate cyclase and transduces signals mainly 
through the cyclic adenosine monophosphate pathway (3, 4). HTR7 has been shown to be 
expressed abundantly both in peripheral tissues like smooth muscle and intestine, and in 
brain regions including the forebrain, hippocampus, hypothalamus, brainstem and 
cerebellum (4-7).
A growing body of evidence has indicated that HTR7 plays a role in the pathophysiology of 
psychiatric disorders. Genome-wide association studies (GWAS) have suggested a 
relationship between HTR7 genetic polymorphisms and schizophrenia and the development 
of alcohol dependence (8-10). HTR7 was also shown to influence behaviors in rodents 
mimic obsessive-compulsive disorder and substance abuse (11, 12). Much attention has been 
devoted to the possible role of HTR7 in depression. HTR7 knock-out mice or mice with 
pharmacological blockade of HTR7 showed antidepressant-like behavior (13-16). A recent 
study showed genetic polymorphisms in HTR7 were associated with hypocortisolism in a 
gender specific manner in African American subjects, suggesting HTR7 may contribute to 
stress system dysregulations (17). Emerging preclinical evidence have suggested that HTR7 
is involved in the action of antidepressants. Several antidepressants, both tricyclics and 
selective serotonin reuptake inhibitors (SSRIs), induce c-fos expression in a fashion that is 
similar to HTR7 activation, while chronic treatment by fluoxetine downregulates HTR7 
expression (18, 19). In addition, blockade of HTR7 by SB-269970, a highly selective HTR7 
antagonist, was found to potentiate the effects of SSRI and norepinephrine reuptake 
inhibitors (NARI) (14). Indeed, several antidepressant and antipsychotic drugs with 
clinically established antidepressant efficacy showed high affinity for HTR7, such as 
amitriptyline, amoxapine, amisulpride, clozapine, aripiprazole, lurasidone, risperidone and 
perospirone (20-23). Thus, the above evidence suggests HTR7 could play an important role 
in SSRI action and may serve as a potential target for the treatment of depression.
SSRIs (e.g. paroxetine and fluoxetine) are the most widely used antidepressants for the 
treatment of major depressive disorder (MDD), however around half of the patients show 
poor response to SSRIs (24). Treatment resistant in MDD is common and evidence show 
that a substantial portion of the treatment resistant MDD patients may later be diagnosed as 
bipolar disorder (BD) (25). BD is a complex and chronic psychiatric condition affecting 
1-2% of the population and, characterized by shifts in mood between manic and depressive 
states (26). Although mania is the most dramatic manifestation of BD, in reality patients 
spend most of their time depressed when ill (27). Though there are many effective 
treatments for mania, treating bipolar depression remains a considerable clinical challenge 
(28). The primary dilemma is the use of antidepressants; there is a risk of inducing a manic 
episode or rapid cycling, though the larger question is one of efficacy. Despite widespread 
safe and seemingly effective use in the community, many controlled trials have failed to 
show efficacy for antidepressants in BD (28). This suggests heterogeneity in drug response 
and possibly disease mechanism. Several large-scale GWAS have examined the association 
between genetic markers and antidepressant response, however the results are difficult to 
replicate and only a limited number of single nucleotide polymorphisms (SNPs) in HTR7 
have been covered (29-31). The overall goal of this study is to identify genes that influence 
SSRI response in BD. In this report, in the first stage, we utilized a cost-effective pooled-
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sequencing strategy to sequence the entire HTR7 gene and its regulatory regions in a 
retrospectively characterized cohort mainly consisting subjects with BD, aimed to 
investigate the genetic association of HTR7 and SSRIs response. In the second stage, we 
replicated the findings from stage one in two independent prospective cohorts consisting of 
patients with MDD (MARS and GENDEP).
Methods
Pooled-sequencing of HTR7 gene in a retrospective cohort
Subjects—All subjects (n=359) were ascertained as part of several cohorts collected for 
genetic studies of BD. All subjects were selected because they had a BD type 1 (BD-I) 
diagnosis, or they had major depression and a first degree relative with BD-I, or 
schizoaffective disorder, bipolar type. Subjects were identified through VA and UCSD 
clinics, as well as, advertisement and patient support groups. All subjects provided written 
informed consent according to UCSD Institutional Review Board approved procedures and 
consent form.
Assessment of SSRI response—All subjects were directly interviewed using the 
Diagnostic Interview for Genetic Studies (DIGS) (32) which had been modified to collect 
information regarding past drug trials. Interviewers underwent a training course, reliability 
was tested regularly and was consistently high. Information from the modified DIGS was 
reviewed by a panel of experienced clinicians along with medical records and information 
from family informants. Patients were queried regarding all their past medication trials 
including a past history of SSRI treatment. Subject’s response to medications over their 
lifetime was assessed based on self-reporting. Blind raters considered all information about 
all medication trials over the patient’s life in order to assess response. Good responders were 
those who were estimated to have 50% reduction in symptoms or episode frequency during 
entire illness. Subject demographic information classified by treatment groups is shown in 
Table 1.
Pooled DNA sequencing—DNA was quantified with PicoGreen and equal quantities 
from each subject were combined into 32 pools (ranging from 11 to 24 subjects per pool) 
grouped by medication (citalopram, paroxetine, fluoxetine and sertraline) and type of 
response (good and poor). The entire HTR7 gene, promoter and 5’ and 3’ UTR regions were 
covered and amplified by 13 long range polymerase chain reactions, generating DNA 
fragments from 10 to 13 kb covering the region of Chr10: 92499978-92623668. We 
performed 2 ×150 bp paired-end, multiplexed sequencing on an Illumina MiSeq sequencer 
(Illumina, San Diego, CA). The quality of raw-reads were examined using FastQC (33) and 
were aligned to human reference genome (GRCh37/hg19) using BWA (34). We used CRISP 
(v0.7) (35) with the default setting as the variant caller and filtered the variants in the VCF 
files that showed EMpass, quality value >100 and minor allele frequency > 0.05. The 
variants were annotated by ANNOVAR (36).
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Replication study I in the Munich Antidepressant Response Signature (MARS) project
The MARS project is a prospective naturalistic study of adult inpatients with depression in 
Germany (30, 37). Diagnoses were based on diagnostic and statistical manual of mental 
diseases (DSM-IV) criteria of a major depressive episode, including first-episode MDD, 
recurrent MDD and BD. The severity of the depressive symptoms was assessed weekly 
based on the 21-item Hamilton Depression Rating Scale (HDRS-21) (38). In this study, we 
included samples with only unipolar depression diagnosis and Caucasian ancestry (n = 837) 
and evaluated the treatment response at week 6. We defined remission as HDRS-21 < 10. 
For further details about the MARS project, see Hennings et al (37).
Replication study II in the Genome-based Therapeutic Drugs for Depression (GENDEP) 
study
GENDEP is a multicenter part-randomized open-label pharmacogenomic study of patients 
with moderate to severe unipolar depression diagnosed according to DSM-IV and 
established in the semi-structured SCAN interview (39). Patients with personal and family 
history of schizophrenia or bipolar affective disorder and current dependence on alcohol or 
drugs were excluded from the study. Response was assessed weekly by three established 
measures of depression severity: the clinician-rated 10-item Montgomery–Åsberg 
Depression Rating Scale (MADRS) (40), the HDRS-17 (41) and the self-report 21-item 
Beck Depression Inventory (42). In this study, we included patients with European ancestry, 
and evaluated the treatment response at week 12. We defined remission as HDRS-17 ≤ 7 
(43). For further details about the GENDEP project, see Uher et al (39, 44).
SNP genotyping
Genotyping of rs7905446 (T/G) in the retrospective cohort was performed using a TaqMan 
SNP genotyping assay (Thermo Fisher Scientific, Waltham, MA, USA) as previously 
described (45). The genotyping success rate was > 95 %. Twenty percent of the samples 
were genotyped in duplicate, with 100% reproducibility. SNP imputation for the MARS and 
GENDEP cohorts see supplementary materials/methods.
Transfection and luciferase reporter assay
HTR7 promoter containing rs7905446 (T/G) SNP was amplified followed by ligation into 
pGL4.26 luciferase reporter vector (Promega, Madison, WI, USA). HT-22 and SK-N-MC 
cell lines were transfected with rs79054446-T or rs7905446-G vectors together with 
pGL4.74 Renilla Luciferase control vector (Promega) using Lipofectamine 3000 reagent 
(Thermo Fisher Scientific). Cells were assayed for luciferase and renilla luciferase activity 
using Dual-Glo Luciferase Assay System (Promega) according to the manufacturer’s 
instruction. Details see supplementary materials/methods.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using the LightShift Chemiluminescent EMSA kit (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. In brief, Hela cells nuclear extracts and 
biotin-labeled probes spanning rs7905446 (T/G) region were incubated at room temperature 
for 40 min followed by electrophoresis separation and transferring to the nylon membrane. 
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The competition reaction was performed using 200-fold molar excess of unlabeled probe. 
For supershift analysis, 1 μg anti-CCAAT/enhancer-binding protein beta (CEBPB) antibody 
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was added to the nuclear extract prior to 
the binding reaction. The DNA-protein complexes were detected using chemiluminescence. 
Details see supplementary materials/methods.
Statistical analysis
The association between drug response and allelic SNPs identified from pooled-sequencing 
were performed using logistic regression (PLINK version 1.9) (46). In this analysis, because 
of the pooling, Caucasians and a small portion of other ethnicities were included. However, 
the association between drug response and rs7905446 genotype was performed using 
logistic regression within the Caucasian population, adjusted for age and sex. χ2 tests were 
used to compare the sex distribution between responders and non-responders. Group 
differences were analyzed using a student’s t-test. A P value of < 0.05 was considered 
nominally statistically significant.
Results
Common SNPs in HTR7 are associated with SSRI response in BD
In the retrospective cohort, we performed pooled-sequencing of HTR7 gene in total of 359 
subjects (Table 1) and examined the association between SSRI treatment response and 
common SNP variations based on an allelic model. We found that 80 out of 169 common 
SNPs survived false discovery rate (FDR) < 0.05 in the paroxetine group and 95% (n = 76) 
of the significant SNPs were located in intronic regions (for the full list see Supplementary 
file). We are particularly interested in the SNP rs7905446 (FDR = 0.0387, Table 2) that was 
located at the promoter region, because several validated transcription factors (TFs) from 
ENCODE database showed binding signals around this region, implicating a functional SNP. 
Further, rs7905446 also showed nominal significance (P = 0.047) in the fluoxetine group 
(Supplementary file) and is in high linkage disequilibrium with the other two top SNPs in 
the 5’ upstream, rs6583737 and rs12254390 (Figure 1). We validated rs7905446 in 
Caucasian subjects using a TaqMan SNP genotyping assay in both paroxetine and fluoxetine 
groups (n=266). The genotype distribution was significantly different between responders 
and non-responders of these two SSRIs (responders: TT vs GT vs GG = 29.7% vs 54.9% vs 
15.4%; non-responders: TT vs GT vs GG = 46.0% vs 41.5% vs 12.5%; Pearson χ2= 6.697, 
P = 0.035). Next, using logistic regression we found that TT genotype was significantly 
associated with poor paroxetine response compared with TG/GG genotypes, when 
controlled for gender and age (TT vs TG/GG: P = 0.005, OR = 5.250; Table 3). When 
combining both paroxetine and fluoxetine groups, TT genotype was again shown to be 
associated with poor response in two SSRIs (TT vs TG/GG: P = 0.008, OR = 2.135; Table 
3). Gender seemed to influence SSRI response in the BD samples, specifically, men were 
more likely to be poor responders (P < 0.001, OR = 2.623; Table 3 and Figure 2). No gender 
× rs7905446 interaction was found in either the paroxetine group or paroxetine + fluoxetine 
groups. Four SNPs including rs7905446 in the fluoxetine showed nominal P < 0.05 
(Supplementary file). No SNPs with nominal P < 0.05 were detected in citalopram and 
sertraline groups.
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Rs7905446 is associated with antidepressant response in unipolar depression in MARS 
and GENDEP cohorts
We next investigated if rs7905446 was associated with antidepressant response in MDD in 
two larger-scale prospective cohorts. The treatment in MARS cohort is naturalistic, selected 
by clinician, which includes a variety of antidepressants such as SSRIs, SNRIs and tricyclics 
etc. We first examined if rs7905446 can predict antidepressant response in general, i.e. 
including all antidepressant drugs. We found TT genotype was significantly associated with 
non-remission status, while TG/GG genotypes predicted treatment remission at week 6, 
when controlling for gender and age (TT vs TG/GG: P = 0.032, OR = 1.385; Table 3). Next, 
we found similar results in patients who underwent SSRI or SNRI treatments (P = 0.044, 
Table 3) or were only treated with SSRI (P = 0.017, Table 3). Other top SNPs (rs6583737 
and rs12254390), that are in high linkage disequilibrium with rs7905446, showed similar 
predictive effects. In the GENDEP cohort, two antidepressants (escitalopram and 
nortriptyline) that represent the two most common mechanisms of action of antidepressants, 
were administered in a part-randomized manner. Interestingly, we found TG/GG genotypes 
predicted remission only in the escitalopram-treated group, escitalopram being an SSRI (P = 
0.008, Table 3) but not nortriptyline which acts like NARI (P = 0.154, Table 3). There was 
no significant gender effect on response to antidepressants in the MARS and GENDEP 
cohorts.
Functional validation of rs7905446
We used a luciferase reporter assay to test if rs7905446 was a functional SNP in two 
neuronal-related cell lines, SK-N-MC (neuroblastoma cell line) and HT-22 (mice 
hippocampal cell line). In both cell lines, we observed the rs7905446-G allele, associated 
with better antidepressant response, exhibited stronger luciferase signals compared with the 
T allele, suggesting a higher promoter activity (SK-N-MC: P < 0.01; HT22: P < 0.001; 
Figure 3). Gender seemed to play a role in modulating antidepressant response: men were 
more than two-fold more likely to become non-responders in the BP retrospective samples 
(Table 3), suggesting estrogen may enhance the effect of antidepressant efficacy. We treated 
the HT-22 cell line with different concentrations of estrogen, and found the high activity of 
the rs7905446-G allele was decreased after estrogen treatment at a concentration of 1μM, 
while the activity of the rs7905446-T allele was not influenced at any concentration tested 
(Figure 3). The Encyclopedia of DNA Elements (ENCODE) database suggests rs7905446 
position overlaps with the binding sites of several potential TFs, including CEBPB, which 
can recruit both activators like EP300 and repressors like the estrogen receptor 1 (ESR1) 
(47, 48). EMSA showed the rs7905446-G allele was able to generate a shift, and when 
adding an anti-CEBPB antibody, a supershift was observed. In contrast, biotin-probe 
spanning the T allele did not show binding potentials of any TFs in the nuclear extract 
(Figure 4).
Discussion
To our knowledge, this is the first study showing a consistent association between a 
functional variant, rs7905446, in HTR7 gene and SSRI response in three independent 
clinical cohorts. We also showed that the rs7905446-G allele which associated with better 
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antidepressants response, displayed higher promoter activity than the T allele, and estrogen 
treatment decreased the promoter activity in only the G allele.
Rs7905446 is associated with response to drugs with different mechanisms of action
SSRIs are chemically diverse and therefore are different from each other in pharmacological 
profiles and clinical efficacy. E.g., citalopram is a racemic mixture and escitalopram is its S-
enantiomer, the latter was shown to have superior efficacy (49). Paroxetine and fluoxetine 
have a high potential to interact with other drugs compared to citalopram and sertraline (50). 
In addition, paroxetine exhibits relatively high affinity to muscarinic receptors and fluoxetine 
shows high affinity to HTR2A/2C receptors. Whether these additional actions of SSRIs will 
influence HTR7 function awaits further investigation. We did not find that rs7905446 was 
associated with response to citalopram or sertraline, suggesting poor power, or that HTR7 is 
not as prominent in the mechanism of action for these two drugs. In the GENDEP cohort, 
we noticed that rs7905446 can predict remission only in patients treated with escitalopram 
but not with nortriptyline, the latter is a tricyclic antidepressant with a hundred times higher 
affinity to norepinephrine transporter than to the serotonin transporter (39). Consistently, in 
the MARS cohort, rs7905446 in predicting remission to SSRI exhibited a much lower P-
value compared to the P-value predicting SSRI + SNRI together. Our result suggested HTR7 
polymorphisms were strongly associated with response to SSRIs but not inhibitors of 
norepinephrine reuptake.
Estrogen plays a role in antidepressant action
In accordance with our findings in the BD cohort, there are reports suggesting SSRI are 
more effective in women than in men (51, 52). In contrast, the effect of gender on 
antidepressant response was not observed in the two depression cohorts, suggesting gender 
may play different roles in BD and unipolar depression. While most studies showed an 
almost equal gender ratio in lifetime prevalence in BD, women were twice as likely than 
men to suffer unipolar depression (52, 53). A number of studies have suggested estrogen as 
antidepressant or as co-adjuvant to facilitate the effect of antidepressants like fluoxetine 
(54). Our work showed a novel mechanism for estrogen’s antidepressant effect: via reduced 
HTR7 expression. We speculate that CEBPB will predominantly recruit activators (e.g. 
EP300) when in conditions of absent or low levels of estrogen, thus we observed a high 
promoter activity in the G allele. In contrast, high levels of estrogen will trigger ESR1 (a 
repressor) competing with other activators to interact with CEBPB, since we observed a 
significant decrease of promoter activity with 1μM β-estradiol treatment but not with 10 nM.
Multiple roles of HTR7
HTR7 has been shown to promote neurite outgrowth (55), dendritic spines and 
synaptogenesis (56), suggesting responders may receive more 5-HT input during 
neurodevelopment or in learning and memory formation. HTR7 may also play a role in 
mediating inflammatory response. Casas-Engel et al showed that serotonin inhibited 
lipopolysaccharide-stimulated proinflammatory cytokine production (e.g. interleukin-12 and 
tumor necrosis factor-α) in macrophages. This effect was blocked by a highly selective 
HTR7 antagonist SB-269970 (57), suggesting an increased HTR7 expression may be 
associated with lower inflammatory cytokine levels. Interestingly, a recent meta-analysis 
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showed that a heightened inflammatory profile may underly the treatment resistance in 
depression (58). Besides, HTR7 seems to have a dual role in regulating γ-aminobutyric acid 
(GABA) synaptic transmission. Activation of HTR7 in raphe nuclei reduces GABA-
mediated inhibition of serotonergic neurons and consequently enhances 5-HT release. 
However in the hippocampus, HTR7 activation was shown to stimulate GABAergic 
interneuron activity (59). HTR7 can form heterodimer with HTR1A, which will inhibit 
HTR1A-mediated activation of Gi protein and G protein-gated potassium channels while 
accelerate agonist-mediated internalization of HTR1A receptor, initiating G protein-
independent signaling pathways such as mitogen-activated protein kinases (60). It has been 
suggested that HTR1A/7 heterodimers are more prevalent in postsynaptic populations in 
depression condition than in physiological condition, leading to an increased internalization 
of postsynaptic HTR1A and neuronal hyper-excitability (61). Decreasing HTR7 activity may 
inhibit HTR1A/7 dimerization-induced neuronal hyper-excitability which may enhance the 
treatment effect of SSRIs. Thus, whether HTR7 expression level can predict SSRI response 
remains elusive but a decrease of HTR7 level seems to be associated with a reduction in 
severity of depressive symptoms.
Limitations
The evaluation of SSRI response in the bipolar cohort was retrospective, thus recall bias may 
be present. However, we previously compared retrospective ratings with prospective 
response on the same patients (n = 40) who completed the prospective arm of a lithium 
study. The patients’ records were then retrospectively and blindly rated using the Alda scale 
(62). We demonstrated a strong correlation between the Alda score and prospectively 
measured response (r = 0.67, P < 0.001) supporting the validity of our retrospective 
assessment. These results are being reported separately; Due to the retrospective assessment 
of the bipolar cohort, we were unable to distinguish if there was a risk for mania/rapid 
cycling after SSRI treatment and the activity of different concomitant medications such as 
mood stabilizer; In MARS study, we cannot examine the association between rs7905440 
genotype and specific type of SSRI due to a lack of detailed drug information. The genetic 
association analyses in MARS and GENDEP studies included imputed data. We cannot 
provide haplotype analysis regarding the SNPs that showed significance since we used 
pooled-sequencing method.
Conclusion remark
Heterogeneity in drug response has been a great challenge in treating mood disorder, which 
may be related to different pathophysiology of the disease and metabolism of the drug, both 
factors thought to be influenced by an individual’s genetic background (63). Understanding 
the relationship between genetic factors and treatment response may allow for the clinical 
implementation of pharmacogenetic tests and the development of personalized treatment in 
patients. Our study showed a functional SNP, rs7905446 in the HTR7 gene was associated 
with response to antidepressants in both bipolar and unipolar depression, which warrants 
further investigation as a potential novel pharmacogenetic diagnostic marker.
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Figure 1. 
Rs7905446 is in high linkage disequilibrium with two top SNPs (rs6583737 and 
rs12254390) in the 5’ upstream region of HTR7 gene. A number of transcription factors 
such as CEBPB in ENCODE database showed binding signals around rs7905446, 
implicating a functional SNP.
Wei et al. Page 14
Mol Psychiatry. Author manuscript; available in PMC 2019 September 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Women gender and individual with rs7905446 GG/GT genotypes showed better response to 
SSRIs (paroxetine + fluoxetine).
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Figure 3. 
The rs7905446-G allele displayed higher luciferase activity compared with the rs7905446-T 
allele tested in two cell lines. High concentration of β-estradiol (E2) treatment significantly 
reduced the activity in only the G allele. **P < 0.01; ***P < 0.001.
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Figure 4. 
Electrophoretic mobility shift assay showed biotin-labeled probe containing the rs7905446-
G can produce a shift (arrow) when incubated with the HeLa cell nuclear extract, suggesting 
an interaction with transcription factors. An anti-CEBPB antibody generated a supershift 
(asterisk), suggesting an interaction with CEBPB transcription factor.
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Table 2.
Top SNPs in HTR7 gene associated with response to paroxetine in the retrospective cohort
SNP ID Position1 Reference
allele
Alternative
allele
P-value FDR
5’ upstream rs6583737* Chr10: 92620789 A G 0.001346 0.0134
rs12254390* Chr10: 92620148 G C 0.008268 0.0241
rs1935346 Chr10: 92622426 T C 0.008589 0.0244
Promoter rs7905446* Chr10: 92619161 T G 0.01695 0.0387
Intron rs4262637 Chr10: 92526004 T C 9.31e-05 0.007868
rs7912164 Chr10: 92519954 T C 5.14e-05 0.007868
rs111631884 Chr10: 92571019 T G 0.00015 0.008709
SNP: single nucleotide polymorphism; FDR: false discovery rate
*
In high linkage disequilibrium with each other
1GRCh37/hg19 assembly
Mol Psychiatry. Author manuscript; available in PMC 2019 September 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wei et al. Page 20
Ta
bl
e 
3.
A
ss
oc
ia
tio
n 
be
tw
ee
n 
H
TR
7 
pr
om
ot
er
 rs
79
05
44
6 
an
d 
an
tid
ep
re
ss
an
ts 
re
sp
on
se
 in
 C
au
ca
sia
ns
 fr
om
 th
re
e c
oh
or
ts
β
O
R
P-
va
lu
e
R
et
ro
sp
ec
tiv
e 
co
ho
rt
 (r
es
po
nd
er
 v
s. 
no
n-
re
sp
on
de
r)
 
Pa
ro
x
et
in
e 
(n=
12
4)
 
 
 
rs
79
05
44
6
1.
65
8
5.
25
0
0.
00
51
 
 
 
Se
x
1.
05
9
2.
88
3
0.
03
32
 
 
 
A
ge
−
0.
02
8
0.
97
3
0.
19
1
 
Pa
ro
x
et
in
e 
+ 
flu
ox
et
in
e 
(n=
26
6)
 
 
 
rs
79
05
44
6
0.
75
8
2.
13
5
0.
00
81
 
 
 
Se
x
0.
96
4
2.
62
3
<
0.
00
12
 
 
 
A
ge
−
0.
00
5
0.
99
5
0.
64
9
Pr
o
sp
ec
tiv
e 
M
A
R
S 
co
ho
rt
 (r
em
itt
er
 v
s. 
no
n-
re
m
itt
er
)
 
SS
RI
 (n
=2
53
)
 
 
 
rs
79
05
44
6
0.
68
1
1.
97
6
0.
01
69
1
 
 
 
Se
x
−
0.
31
0
0.
73
3
0.
27
2
 
 
 
A
ge
−
0.
01
3
0.
98
7
0.
19
0
 
SS
RI
 +
 S
N
RI
 (n
=5
42
)
 
 
 
rs
79
05
44
6
0.
37
8
1.
46
0
0.
04
41
 
 
 
Se
x
−
0.
31
9
0.
72
7
0.
08
6
 
 
 
A
ge
0.
00
09
1.
00
1
0.
89
7
 
A
ll 
an
tid
ep
re
ss
an
ts 
(n=
83
7)
 
 
 
rs
79
05
44
6
0.
32
6
1.
38
5
0.
03
21
 
 
 
Se
x
−
0.
15
6
0.
85
6
0.
29
9
 
 
 
A
ge
0.
00
03
1.
00
0
0.
95
8
Pr
o
sp
ec
tiv
e 
G
EN
D
EP
 co
ho
rt
 (r
em
itt
er
 v
s. 
no
n-
re
m
itt
er
)
 
Es
ci
ta
lo
pr
am
 (n
=4
32
)
 
 
 
rs
79
05
44
6
0.
51
2
1.
66
9
0.
00
83
 
 
 
Se
x
−
0.
29
7
0.
74
3
0.
17
8
Mol Psychiatry. Author manuscript; available in PMC 2019 September 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wei et al. Page 21
β
O
R
P-
va
lu
e
 
 
 
A
ge
−
0.
03
6
0.
97
0
0.
00
1
 
 
 
Ce
nt
er
 ID
0.
01
0
1.
01
0.
68
1
 
N
or
tri
pt
yl
in
e 
(n=
32
8)
 
 
 
rs
79
05
44
6
−
0.
36
6
0.
69
4
0.
15
4
 
 
 
Se
x
−
0.
28
0
0.
88
9
0.
30
2
 
 
 
A
ge
−
0.
00
4
0.
99
6
0.
71
3
 
 
 
Ce
nt
er
 ID
−
0.
03
5
0.
96
6
0.
21
9
 
Es
ci
ta
lo
pr
am
 +
 n
or
tri
pt
yl
in
e 
(n=
73
0)
 
 
 
rs
79
05
44
6
0.
13
2
1.
14
1
0.
39
0
 
 
 
Se
x
−
0.
11
2
0.
89
4
0.
47
6
 
 
 
A
ge
−
0.
02
4
0.
97
6
<
0.
00
1
 
 
 
Ce
nt
er
 ID
−
0.
00
7
0.
99
3
0.
72
0
SS
RI
: S
el
ec
tiv
e 
se
ro
to
ni
n 
re
up
ta
ke
 in
hi
bi
to
rs
; S
N
RI
: S
er
ot
on
in
 a
nd
 n
or
ep
in
ep
hr
in
e 
re
up
ta
ke
 in
hi
bi
to
rs
1 T
T 
vs
 T
G
/G
G
 u
sin
g 
lo
gi
sti
c 
re
gr
es
sio
n 
ad
jus
ted
 fo
r g
en
de
r a
nd
 ag
e
2 M
en
 v
s w
o
m
en
 u
sin
g 
lo
gi
sti
c 
re
gr
es
sio
n 
ad
jus
ted
 fo
r r
s79
05
44
6 a
nd
 ag
e
3 T
T 
vs
 T
G
/G
G
 u
sin
g 
lo
gi
sti
c 
re
gr
es
sio
n 
ad
jus
ted
 fo
r g
en
de
r, a
ge
 a
nd
 c
en
te
r I
D
Mol Psychiatry. Author manuscript; available in PMC 2019 September 16.
